Tyson Smyth

Tyson Smyth is currently serving as Associate Director of Drug Product and Formulation Development at Lundbeck since June 2022. Prior experience includes roles as Senior Scientist II and Senior Scientist in Biologics Product Development at Nektar Therapeutics, where Tyson was integral in authoring CMC drug product sections for regulatory submissions, evaluating formulation robustness, and leading stability studies. Previous experience also encompasses Formulation Development Scientist III and II positions at Revance Therapeutics, contributing to formulation cycles for protein therapeutics and overseeing tech transfers for cell-based potency assays. Tyson holds a Ph.D. in Pharmaceutical Sciences from the University of Colorado Denver and a B.S. in Molecular Cellular Developmental Biology from the University of Colorado Boulder. Tyson's extensive expertise includes drug delivery, product stability, and lyophilization, cultivated over years of industry experience and academic research.